(Q34458371)

2 August 2017

1 reference

title

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors (English)

1 reference

2 August 2017

1 reference

P F Smith

1

1 reference

2 August 2017

R DiCenzo

series ordinal

2

1 reference

2 August 2017

G D Morse

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2001

1 reference

Clinical Pharmacokinetics

2 August 2017

published in

1 reference

2 August 2017

volume

40

1 reference

2 August 2017

issue

12

1 reference

2 August 2017

page(s)

893-905

1 reference

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

2 August 2017

cites work

1 reference

12 December 2020

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

1 reference

12 December 2020

In Vitro Blood–Brain Barrier Permeability of Nevirapine Compared to Other HIV Antiretroviral Agents

1 reference

12 December 2020

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

1 reference

12 December 2020

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

1 reference

12 December 2020

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

1 reference

12 December 2020

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

12 December 2020

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

1 reference

12 December 2020

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

12 December 2020

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

1 reference

12 December 2020

Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Lack of pharmacokinetic interaction between nelfinavir and nevirapine

1 reference

12 December 2020

HIV-1 drug resistance in newly infected individuals

1 reference

12 December 2020

Nelfinavir and nevirapine interaction?

1 reference

12 December 2020

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

1 reference

12 December 2020

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

12 December 2020

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

12 December 2020

In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite

1 reference

12 December 2020

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma

1 reference

12 December 2020

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

1 reference

12 December 2020

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team

1 reference

12 December 2020

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

1 reference

12 December 2020

Variability in trough plasma saquinavir concentrations in HIV patients--a case for therapeutic drug monitoring

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1 reference

12 December 2020

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

1 reference

12 December 2020

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

12 December 2020

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

1 reference

12 December 2020

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

1 reference

12 December 2020

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

1 reference

12 December 2020

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans

1 reference

12 December 2020

Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients

1 reference

12 December 2020

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

1 reference

12 December 2020

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection

1 reference

12 December 2020

10.2165/00003088-200140120-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1048700706

0 references

1 reference